|
Published by: CHI Insight Pharma Reports
Published: Jan. 1, 2008 - 180 Pages
Table of Contents
- Chapter 1
- INTRODUCTION
- 1.1. Biomarker Definitions
- 1.2. Organization of the Report
- Chapter 2
- IN VIVO MOLECULAR IMAGING TECHNOLOGIES
- 2.1. Historical Introduction
- 2.2. Imaging Technologies
- Computed Tomography
- Positron Emission Tomography
- Single Photon Emission Computed Tomography
- Magnetic Resonance Imaging
- Ultrasound
- Optical Imaging
- 2.3. Combination Technologies
- 2.4. Molecular and Functional Imaging
- Chapter 3
- IMAGING BIOMARKERS IN DRUG DEVELOPMENT
- 3.1. Preclinical Development
- 3.2. Clinical Development
- 3.3. Therapeutic Areas
- Cancer
- Cell Proliferation or Metabolism
- Apoptosis
- Angiogenesis
- Hypoxia
- Other Parameters
- Neurological Disease
- Alzheimer's Disease
- Parkinson's Disease
- Cardiovascular Disease
- Inflammatory and Autoimmune Disease
- Chapter 4
- MOLECULAR IMAGING IN DIAGNOSTICS
- 4.1. Cancer
- 4.2. Cardiovascular Disease
- 4.3. Neurological Disease
- Chapter 5
- CONSORTIA, GOVERNMENT, AND REGULATORY CONSIDERATIONS
- 5.1. Consortia and Professional Society Involvement
- Biomarkers Consortium
- Oncology Biomarker Qualification Initiative (OBQI)
- Uniform Protocols for Imaging in Clinical Trials (UPICT)
- Imaging Response Assessment Teams (IRATs)
- 5.2. Government Involvement
- NIH Molecular Libraries and Imaging Roadmap
- Network for Translational Research: Optical Imaging (NTROI)
- Alzheimer's Disease Neuroimaging Initiative (ADNI)
- Institute for Molecular Technology (IMT)
- National Oncologic PET Registry (NOPR)
- 5.3. FDA Regulatory Guidance
- 5.4. National Academy of Sciences Report
- Chapter 6
- MARKET CONSIDERATIONS
- 6.1. The Molecular Imaging Market Ecology
- Radiopharmaceuticals
- Instruments
- Software
- 6.2. Market Analysis and Dynamics
- Facilitation of Imaging Agent Development
- PET Versus SPECT
- 6.3. Drug Discovery and Development Market
- Large Company Business Models
- The Convergence of In Vitro and In Vivo Diagnostics
- 6.4. Deals in Molecular Imaging
- Categorization of Deals
- Market Size and Growth Projects
- Chapter 7
- EXPERT INTERVIEWS
- Sudeep Chandra, PhD, General Manager of Molecular Imaging, Philips Healthcare
- Terry A. Colip, Managing Partner and CFO, Cell>Point, LLC
- J. James Frost, MD, PhD, Professor of Radiology and Psychiatry, Yale University, School of Medicine
- Antony Gee, PhD, Director of PET and Radiotracer Development, GlaxoSmithKline
- Franz Hefti, PhD, Chief Scientific Officer, Avid Radiopharmaceuticals
- Patrick McConville, PhD, Director of Imaging, MIR Preclinical Services
- Jean-Luc Vanderheyden, PhD, Global Molecular Imaging Leader, GE Healthcare
- APPENDIX
- INSIGHT PHARMA REPORTS MOLECULAR IMAGING SURVEY-OCTOBER 2007
- Observations from the Survey
- References
- Company Index with Web Addresses
AbstractThe rapidly emerging field of molecular imaging is poised to open new vistas for basic researchers, scientists working in drug discovery and development, and physicians. This new report delves fully into:
- The history, evolution, and potential of molecular imaging
- The technologies in use today and under development for the future
- Applications in drug development and diagnostic medicine
- Market dynamics that are shaping and reshaping commerce in molecular imaging instruments and reagents
- Regulatory aspects of the field
- Interviews with experts active as either providers or users of molecular imaging
- Results of an online survey of individuals in pharmaceutical and biotechnology companies and institutional researchers
Little more than 5 years old, the postgenomic field of molecular imaging is undergoing rapid research and commercial development, driven largely by big pharma’s burgeoning interest in biomarkers as crucial for decision support in preclinical and early clinical development.
The term biomarker is often associated with the detection or measurement (in vitro) of expressed genes, proteins, or metabolites in biological fluids. To drug developers, however, biomarker can refer equally well to morphological, functional, or molecular measurements made in vivo using medical imaging equipment, such as:
- Computed tomography (CT)
- Magnetic resonance imaging (MRI)
- Positron emission tomography (PET)
- Ultrasound
- Optical scanners
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
